Search results
Showing 2801 to 2850 of 3041 results for all
Discontinued Reference number: GID-TA10566
The NICE commercial liaison team aim to reduce the workload for the NHS and frontline staff by making commercial agreements more straightforward.
Appraisal is the process of determining which records have continuing business or historical value from those which have no further value and should be disposed of appropriately.
Check our list of appointed suppliers to find out which knowledge resources and services they can offer.
Clarification on demonstrating patient access to medicines and treatments recommended by NICE Technology Appraisal (TA) or Highly Specialised Technologies (HST) guidance.
Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.
The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals.
Highly specialised technologies evaluation committee members
Biographies for each member of the highly specialised technologies evaluation committee.
Pre-exposure prophylaxis (PrEP) became routinely available through sexual health clinics in 2020, with NICE recommending the tablets for people at high risk of HIV in 2021.
Tackling variation in rehab for people with neurological conditions
NICE has recommended a standardised approach for rehabilitation, to address the variation of care experienced by millions of people with chronic neurological conditions.
Find out how and where you can reuse NICE's content. Includes use of our content in the UK, use of our content internationally, use of our content for AI purposes, our content assurance process, and our information asset register.
Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.
Our chief executive, Dr Sam Roberts, welcomes the government's 10 Year Plan for healthcare
The government's 10 Year Plan marks a pivotal moment for healthcare and strengthens NICE’s role.
(lung) conditions Asthma inhalers and climate change Show Full list of all PDAs choosing between medical or surgical abortion from 14...
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
Data on the cancer recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.
Biographies and registered interests for members of the Technology Appraisal Committee A
We explore the ongoing debate around NICE’s cost-effectiveness thresholds and what the future holds.
Same time decisions on licensing and value - what pharmaceutical companies need to know
Learn how NICE and MHRA are launching an aligned pathway to accelerate patient access to medicines and provide a more efficient route for industry.
NICE has a key role in UK licensing and the evaluation of and access to new and innovative products for the health system.
Day-to-day decision making is the responsibility of NICE's executive team.
Our first guideline on kidney cancer recommends better use of biopsies to avoid surgery
New guidance aims to reduce variation in treatment and prevent unnecessary surgery, improving care for patients and supporting healthcare professionals.
us"}}]} Structure of NICE NICE is an organisation made up of people who all share the same mission: helping practitioners and...
NICE is committed to supporting the national agenda for achieving a sustainable health and care system.
sustainability The healthcare system in England is responsible for 5% of all UK carbon emissions. The NHS has pledged to become carbon...
NICE wants as many people as possible to be able to use our services, and we have designed it to be accessible.
We assess the efficacy and safety of interventional procedures used for treatment or diagnosis to determine whether they work well enough and are safe enough for use in the NHS.
Breakthrough life-extending combination treatment for advanced bladder cancer recommended by NICE
The new treatment offers hope to thousands living with advanced urothelial cancer, with clinical trials showing overall survival rates were almost twice as long compared to standard treatment.
International collaboration with NICE
First NICE-curated guideline announced ahead of World Duchenne Awareness Day
In the lead-up to World Duchenne Awareness Day on Sunday 7 September, we’re pleased to announce the completion of our first assessment of an externally developed clinical guideline.
Recommendations in NICE’s type 2 diabetes guideline update, published today, will enhance the use of SGLT-2 inhibitors in primary care and address these health inequalities.
Biggest shake-up in type 2 diabetes care in a decade announced
Millions of people are set to benefit from earlier access to newer type 2 diabetes treatments – the biggest shake-up in care for a decade – as part of NICE’s commitment to re-evaluate priority clinical pathways described in the 10-Year Health Plan for the NHS.
Partner with NICE in our research work
Technology appraisal guidance makes recommendations on the use of new and existing medicines and other treatments within the NHS.
Smoking cessation positively impacts all 5 clinical areas identified by Core20PLUS5 adults.
Providing an advisory service for international health organisations, ministries and government agencies whose task is to improve evidence-based decision making in health and social care
studies to see how we work with global partners to achieve better health for all. Strengthening Egypt's healthcare system through...
Our stakeholders are involved in the development of NICE guidance and quality standards to ensure that the recommendations are relevant, practical, and meet the needs of those affected by the health or social care issues addressed.
Early Cancer Diagnosis: 75% of cases diagnosed at stage 1 or 2 by 2028.
Information and benefits about shared decision making. Includes links to patient decision aids.
A clear focus on Chronic Obstructive Pulmonary Disease (COPD) driving up uptake of Covid, Flu and Pneumonia vaccines to reduce infective exacerbations and emergency hospital admissions due to those exacerbations.
contribute your views, we'd like to hear from you. We welcome applicants from all backgrounds. We're especially looking to increase...
Guide for lay members who we've invited to sit on one of NICE's committees, panels, or groups.
People coming off obesity medication or finishing a weight management programme should be offered support to help keep the weight off and stay healthy long-term, according to our updated quality standard.
NICE Advice - a fee-based advisory service for pharmaceutical and healthtech companies seeking to enter the NHS market,
"name":"Home"}}]} Terms and conditions The NICE websites ("the websites") and all information contained in them are available for use...
Final decision on cerliponase alfa for Batten disease treatment confirmed
In final draft guidance published today we've confirmed that we’re unable to recommend cerliponase alfa (also called Brineura and made by BioMarin) for routine NHS use in treating neuronal ceroid lipofuscinosis type 2 (CLN2), a rare and life-limiting form of Batten disease.
Embed NICE content in your digital products and services with our syndication API.
Evidence standards framework (ESF) for digital health technologies
NICE standards for innovators of digital health technologies and NHS commissioners
The NHS 2022/23 priorities and operational planning guidance, sets a lead role for Integrated Care Systems in tackling health inequalities.